Many patients with psychotic symptoms respond poorly to treatment. Various approaches have been made to classify these patients according to treatment response. However, existing classifications have been criticized for various reasons and a new classification system is needed. Further, no satisfactory explanation of the poor treatment response has been apparent. The general aim of this thesis was therefore to develop and validate a new classification method of functional remission in a naturalistic population of patients with psychosis and to utilize this classification to investigate the population from genetic, drug treatment, insight and social network points of view. Data for this cross-sectional study of patients (n=123) attending the...
A large body of research indicates that weak expressions of positive psychotic symptoms ("psychotic ...
Aim: This review summarises the present knowledge of associations between pharmacogenetics and thera...
Recent important advancements in genomic research have opened the way to new strategies for public h...
Many patients with psychotic symptoms respond poorly to treatment. Various approaches have been made...
Background: Personalised medicine (pm) means treatment that specifically targets the needs of indivi...
BACKGROUND: Personalised medicine (pm) means treatment that specifically targets the needs of indivi...
Schizophrenia is a severe neuropsychiatric disorder that affects around 0.5–1% of the population. Re...
Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or o...
Treatment of schizophrenia with antipsychotic drugs is frequently sub-optimal. One reason for this m...
Schizophrenia, characterised by psychotic symptoms and in many cases social and occupational decline...
Evidence suggests that social networks of patients with psychotic disorders influence symptoms, qual...
Background: Evidence suggests that social networks of patients with psychotic disorders influence sy...
Pharmacogenetic studies have demonstrated significant associations between several candidate genes (...
Schizophrenia is a severe neuropsychiatric disorder that affects approximately 0.5-1% of the populat...
A large body of research indicates that weak expressions of positive psychotic symptoms ("psychotic ...
Aim: This review summarises the present knowledge of associations between pharmacogenetics and thera...
Recent important advancements in genomic research have opened the way to new strategies for public h...
Many patients with psychotic symptoms respond poorly to treatment. Various approaches have been made...
Background: Personalised medicine (pm) means treatment that specifically targets the needs of indivi...
BACKGROUND: Personalised medicine (pm) means treatment that specifically targets the needs of indivi...
Schizophrenia is a severe neuropsychiatric disorder that affects around 0.5–1% of the population. Re...
Introduction: Genetic polymorphisms of cytochrome P450 (CYP) may predict the treatment response or o...
Treatment of schizophrenia with antipsychotic drugs is frequently sub-optimal. One reason for this m...
Schizophrenia, characterised by psychotic symptoms and in many cases social and occupational decline...
Evidence suggests that social networks of patients with psychotic disorders influence symptoms, qual...
Background: Evidence suggests that social networks of patients with psychotic disorders influence sy...
Pharmacogenetic studies have demonstrated significant associations between several candidate genes (...
Schizophrenia is a severe neuropsychiatric disorder that affects approximately 0.5-1% of the populat...
A large body of research indicates that weak expressions of positive psychotic symptoms ("psychotic ...
Aim: This review summarises the present knowledge of associations between pharmacogenetics and thera...
Recent important advancements in genomic research have opened the way to new strategies for public h...